Literature DB >> 24316105

Prevention of hepatocellular carcinoma resulting from hepatitis B: are we there yet?

Adrian M Di Bisceglie1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24316105      PMCID： PMC5497489          DOI： 10.1016/j.cgh.2013.11.027

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  13 in total

1.  Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.

Authors:  George V Papatheodoridis; Spilios Manolakopoulos; Giota Touloumi; Georgia Vourli; Maria Raptopoulou-Gigi; Irini Vafiadis-Zoumbouli; Themistoklis Vasiliadis; Kostas Mimidis; Charalambos Gogos; Ioannis Ketikoglou; Emanuel K Manesis
Journal:  Gut       Date:  2011-01-26       Impact factor: 23.059

2.  Risk and predictors of mortality associated with chronic hepatitis B infection.

Authors:  Uchenna H Iloeje; Hwai-I Yang; Chin-Lan Jen; Jun Su; Li-Yu Wang; San-Lin You; Chien-Jen Chen
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08       Impact factor: 11.382

3.  Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

Authors:  Jong Ryul Eun; Heon Ju Lee; Tae Nyeun Kim; Kyeung Soo Lee
Journal:  J Hepatol       Date:  2010-04-04       Impact factor: 25.083

4.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

Authors:  Timothy R Morgan; Marc G Ghany; Hae-Young Kim; Kristin K Snow; Mitchell L Shiffman; Jennifer L De Santo; William M Lee; Adrian M Di Bisceglie; Herbert L Bonkovsky; Jules L Dienstag; Chihiro Morishima; Karen L Lindsay; Anna S F Lok
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

7.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.

Authors:  Tetsuya Hosaka; Fumitaka Suzuki; Masahiro Kobayashi; Yuya Seko; Yusuke Kawamura; Hitomi Sezaki; Norio Akuta; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  Hepatology       Date:  2013-03-06       Impact factor: 17.425

9.  Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.

Authors:  Stuart C Gordon; Lois E Lamerato; Loralee B Rupp; Jia Li; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Vinutha Vijayadeva; Joseph A Boscarino; Emily M Henkle; Nancy Oja-Tebbe; Mei Lu
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-06       Impact factor: 11.382

Review 10.  Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.

Authors:  Rebecca L Morgan; Brittney Baack; Bryce D Smith; Anthony Yartel; Marc Pitasi; Yngve Falck-Ytter
Journal:  Ann Intern Med       Date:  2013-03-05       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.